From Detection to Decision: Risk-Based Immunogenicity Testing
Immunogenicity describes treatment‑induced B‑ and T‑cell responses to therapeutics and represents a major hurdle for drug development, due to the potential impact on patient safety…
Good Manufacturing Practice ligand binding and potency assays are essential for ensuring the quality, safety, and regulatory compliance of biopharmaceutical…
